HealthTech.euabout 2 hours ago
Efferon raises €4.3M for sepsis treatment expansion
2 min read
Efferon, a biotech company making hemoadsorption devices that remove endotoxins and inflammatory mediators from the bloodstream, raised €4.3 million from existing private investors in the DACH region. The funds will expand Efferon LPS and Efferon NEO in Europe, India and Latin America, grow its 21-distributor network and support regulatory work. Revenue exceeded €1.1 million in 2025.
Level
Hype check
Tap to vote and see what everyone thinks.
